



## The latest evidence in the Management of Neuromuscular Blockade

**News: Uppsala, June 3, 2020. Senszime AB (publ) today announces that they are the proud sponsor of a free webinar on the management of neuromuscular blockade.**

This educational webinar is designed to provide insight into the latest evidence of post-operative residual neuromuscular blockade, antagonist strategies to reduce PORC and a technology review of current monitoring technologies.

Meet the experts and join us on Wednesday June 17<sup>th</sup>! Space is limited, book your place here:

REGISTER LINK: [Early session](#)

REGISTER LINK: [Late session](#)



**WEBINAR**

*Transforming your Anesthesia Practice:*

**The latest evidence in the Management of Neuromuscular Blockade**

**Wednesday, June 17th**

Early Session 10 AM EDT / 7AM PDT / 4PM CET  
Late Session 6 PM EDT/3 PM PDT

**Register Now!**

	<b>Glenn S. Murphy, MD</b> Chair of Anesthesiology Research and Education NorthShore University HealthSystem		<b>Sorin J. Brill, MD FCARS (Hon)</b> Professor of Anesthesiology and Perioperative Medicine Mayo Clinic, College of Medicine
---	---	---	---

Senzime's TetraGraph neuromuscular monitor is a unique digital system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph stimulates a peripheral nerve and measures, analyzes and displays in real-time the muscle function in surgical patients who receive NMBAs as part of their general anesthetic.

**For further information, please contact:**

Pia Renaudin, CEO of Senszime AB

Tel: +46 (0)70-813 34 17, email: [pia.renaudin@senzime.com](mailto:pia.renaudin@senzime.com)

## **TO THE EDITORS**

### **About Sensime**

Sensime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Sensime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se is Certified Adviser for Sensime. [www.sensime.com](http://www.sensime.com)